These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24316634)

  • 21. US venture capital for biotechnology.
    Dibner MD; Trull M; Howell M
    Nat Biotechnol; 2003 Jun; 21(6):613-7. PubMed ID: 12776144
    [No Abstract]   [Full Text] [Related]  

  • 22. US government previews biotech survey.
    Goho A
    Nat Biotechnol; 2003 Aug; 21(8):837-8. PubMed ID: 12894185
    [No Abstract]   [Full Text] [Related]  

  • 23. Biotech's wonder ride.
    Rynecki D
    Fortune; 2000 Mar; 141(5):435-6. PubMed ID: 10788046
    [No Abstract]   [Full Text] [Related]  

  • 24. Is your biotech giving away the store?
    Jacobs T
    Nat Biotechnol; 2002 Nov; 20(11):1079. PubMed ID: 12410245
    [No Abstract]   [Full Text] [Related]  

  • 25. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 26. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 27. Sustaining agbiotechnology through lean times.
    McElroy D
    Nat Biotechnol; 2003 Sep; 21(9):996-1002. PubMed ID: 12949560
    [No Abstract]   [Full Text] [Related]  

  • 28. Boutiques reborn in 2003.
    Surendran A
    Nat Biotechnol; 2004 Mar; 22(3):353-4. PubMed ID: 15017987
    [No Abstract]   [Full Text] [Related]  

  • 29. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

  • 30. Back to life.
    Smaglik P
    Nature; 2004 May; 429(6990):483. PubMed ID: 15164076
    [No Abstract]   [Full Text] [Related]  

  • 31. A rollercoaster ride.
    Jacobs T
    Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
    [No Abstract]   [Full Text] [Related]  

  • 32. Hwang scandal hits Korean biotech hard.
    Fuyuno I
    Nature; 2006 Jan; 439(7074):265. PubMed ID: 16421542
    [No Abstract]   [Full Text] [Related]  

  • 33. John McCamant on the future of biotech. Interview by Dennis Murray.
    McCamant J
    Med Econ; 2002 Jan; 79(1):43-6. PubMed ID: 11807995
    [No Abstract]   [Full Text] [Related]  

  • 34. Biotech boom prompts fears of bust.
    Ledford H
    Nature; 2013 Aug; 500(7464):513. PubMed ID: 23985852
    [No Abstract]   [Full Text] [Related]  

  • 35. European markets target foreign biotechs.
    Louët S
    Nat Biotechnol; 2003 Jul; 21(7):719. PubMed ID: 12833075
    [No Abstract]   [Full Text] [Related]  

  • 36. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 37. Biotech parks proliferate, despite concerns over sustainability.
    Jia H; Jayaraman KS; Orellana C
    Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
    [No Abstract]   [Full Text] [Related]  

  • 38. Little science, big bucks.
    DeFrancesco L
    Nat Biotechnol; 2003 Oct; 21(10):1127-9. PubMed ID: 14520387
    [No Abstract]   [Full Text] [Related]  

  • 39. Upward trend in financing continues, but fewer feel flush.
    Lawrence S
    Nat Biotechnol; 2007 Jan; 25(1):3. PubMed ID: 17211374
    [No Abstract]   [Full Text] [Related]  

  • 40. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.